Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space, where the company is present in flu and RSV prevention.

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV.

In RSV, Sanofi is represented by Beyfortus, an FDA-approved antibody drug that works like a vaccine, providing infants and young children protection from the respiratory pathogen.

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline. Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd, a privately held ...

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and ...

In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is ...